Humana Stock Gains on Medicare Advantage Payment Proposal
In recent trading sessions, shares of Humana Inc. (NYSE: HUM), along with UnitedHealth Group Inc. and CVS Health Corp., saw a significant uptick following a governmental proposal aimed at boosting payments for Medicare Advantage plans in the upcoming years. The Centers for Medicare and Medicaid Services (CMS) has unveiled that payments to these plans could witness an average rise of 4.3%, which translates to a more nuanced 2.2% adjustment when factoring in anticipated changes in patient risk scores.
Positive Market Reaction
This proposed increase, which would mark the most substantial rise since 2023, serves as a welcome shift from previous years where insurers were vocal about the inadequacy of the rates to cover escalating medical expenses. Following this news, Humana's stock experienced a 4% jump, while UnitedHealth rose by 3.9% and CVS noted an increase of 2.7%.
Financial Implications of the Proposal
If the proposal is adopted under the incoming administration, it could lead to an impressive additional $21 billion in payments in 2026 compared to what was slated for 2025. This development comes in the wake of the previous administration's efforts to limit payments to Medicare Advantage plans, which had faced scrutiny over potential overcharges attributed to inflated patient risk scores.
Analysts Weigh In
Renowned TD Cowen analyst Ryan Langston commented on the preliminary rate increase, noting, "The headline rate in the Advance Notice of +2.23% exceeded our earlier projected range of 0% to +2%." This anticipated rise in rates could enhance the stabilization of supplemental benefits, particularly when juxtaposed with the previous two years characterized by negative rate trends.
The Future of Medicare Advantage Plans
The current CMS proposal remains in draft form, with a final announcement expected in the coming months. Traditionally, the Medicare Advantage rate proposals are made public between late January and early February. This increase signals optimism for the industry and hints at a potential shift in policy favorability under a new administration.
Projected Spending on Medicare Plans
Looking ahead, it’s projected that the United States will allocate approximately $9.2 trillion over the next decade toward payments for private Medicare plans. In 2024, Humana, UnitedHealth, and CVS collectively offered over half of the Medicare Advantage plans, which represented more than half of all Medicare beneficiaries at an astounding cost of $455 billion in 2023, excluding payments associated with Part D drug plans.
Monitoring the Impact on Earnings
The ramifications of these proposed changes on the earnings of health care companies will largely hinge on the actual medical costs incurred in 2026, along with updates to specific country benchmarks and the respective Star ratings of each company. The industry is poised to closely observe how these rates influence enrollment growth for Medicare Advantage, as well as their broader impact on market dynamics.
Frequently Asked Questions
What is the recent proposal concerning Medicare payments?
The recent CMS proposal suggests an average payment increase of 4.3% for Medicare Advantage plans, including a 2.2% adjustment for patient risk.
How has the stock market reacted to this proposal?
Following the announcement, shares of Humana increased by 4%, UnitedHealth by 3.9%, and CVS by 2.7%.
What are the potential financial implications of this proposal?
The proposal could lead to an additional $21 billion in Medicare Advantage payments in 2026 compared to forecasts for 2025.
When is the final decision on the payment rates expected?
The final notice on the payment rates from CMS is anticipated to be released in April.
How much is projected to be spent on Medicare over the next decade?
The U.S. is projected to spend around $9.2 trillion on private Medicare plans in the coming ten years.
